The finding that SOX2-mediated the Akt/mTOR signaling pathway induces stemness and sorafenib resistance in HCC complements the stemness-related molecular mechanisms of sorafenib resistance and further confirms the combination therapy of the Akt/mTOR signaling pathway inhibitor and sorafenib for HCC is feasible. This evidence concerns the gene MTOR and hepatocellular carcinoma.